Cesca Therapeutics (KOOL) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cesca Therapeutics Reports Second Quarter Fiscal 2015 Results
February 12, 2015 4:00 PM ESTCompany to Provide an Update on the Status of Its IDE Submission to the FDA for a Phase III Pivotal Clinical Trial for the Treatment of Patients With Critical Limb Ischemia
Management Will Hold a Conference Call Today at 2:00pm Pacific (5:00pm Eastern)
RANCHO CORDOVA, Calif., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (Nasdaq: KOOL), an autologous cell-based regenerative medicine company, today reported financial results for the second quarter of fiscal 2015 and provided an update on the progress of its clinical programs.
"We made good... More
